Monitor pricing announcement for discount to last close of $32.28. The offering overhang will pressure shares near-term; watch for final terms and any insider participation. Cash runway extension into Q3 2028 is positive but secondary to dilution.
Price Chart
Executive Summary
Neurogene filed a preliminary prospectus supplement for an underwritten public offering of common stock and pre-funded warrants. All key terms (size, price, proceeds) are placeholder/undisclosed. The offering will dilute existing shareholders, with proceeds intended to fund NGN-401 clinical development and pre-commercial activities, extending cash runway into Q3 2028.
Key Facts
- Offering of common stock and pre-funded warrants; all terms (size, price, proceeds) are undisclosed placeholders.
- Net tangible book value as of March 31, 2026 was $237.8 million ($15.23 per share).
- Proceeds will fund NGN-401 clinical development, pre-commercial activities, and working capital; cash runway extended into Q3 2028.
- Existing ATM facility has $119 million remaining; 209,529 shares sold between March 31 and filing date.
- 60-day lock-up for company and insiders; underwriters have 30-day option to purchase additional shares.
Financial Impact
Undisclosed offering size; dilution to existing shareholders expected. Net tangible book value per share was $15.23 as of March 31, 2026.
Risk Factors
- Immediate and substantial dilution to existing shareholders.
- Undisclosed offering size could be larger than expected.
- Pre-revenue clinical-stage biotech with no approved products; reliance on NGN-401 success.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001628280-26-046237 |
| Document: 0001628280-26-046237-index-headers.html | 0001628280-26-046237 |
| Document: 0001628280-26-046237-index.html | 0001628280-26-046237 |
| Document: 0001628280-26-046237.txt | 0001628280-26-046237 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 7, 2026 19d ago | SC 13G | $25.87 | awaiting T+20 | — | $23.54 (−9.01%) |
Oct 6, 2026 20d ago | SC 13G | $25.45 | awaiting T+20 | — | $23.54 (−7.50%) |
Aug 11, 2026 10w ago | 8-K | $36.55 $37.88 | ▲ +3.64% | ▲ +4.70% | $23.54 (−35.60%) |
Jun 30, 2026 16w ago | 424B5 | $33.88 $33.66 | ▲ +0.65% | ▼ −1.54% | $23.54 (+30.52%) |
Jun 29, 2026 17w ago | 8-K | $32.28 $34.90 | ▲ +8.12% | ▲ +8.40% | $23.54 (−27.08%) |
Jun 8, 2026 20w ago | 8-K | $28.60 $32.56 | ▲ +13.85% | ▲ +12.21% | $23.54 (−17.69%) |
Apr 20, 2026 27w ago | 8-K | $27.74 $27.98 | ▲ +0.87% | ▼ −3.34% | $23.54 (−15.14%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers